Render Target: STATIC
Render Timestamp: 2024-12-26T11:20:58.424Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-04-05 20:46:46.086
Product last modified at: 2024-05-30T07:01:21.987Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

FKBP10 Antibody #92445

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 78
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FKBP10 Antibody recognizes endogenous levels of total FKBP10 protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro425 of human FKBP10 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    FK506-binding proteins (FKBPs) are a large family of conserved proteins characterized by the presence of one or more peptidyl-prolyl cis-trans isomerase (PPIase) domains. The founding member FKBP12 was originally identified as a non-covalent binding protein of FK506 and rapamycin, two widely used immunosuppressive drugs, and mediated their immunosuppressive activity. The FKBP12-FK506 complex specifically targets the Ca2+-dependent serine-threonine phosphatase calcineurin, and the FBKP12-rapamycin complex acts on mTOR (mammalian target of rapamycin). While both FK506 and rapamycin bind to the PPIase domain and inhibit PPIase activity of FKBP12, the inhibition of PPIase activity per se does not contribute to their immunosuppressive activity. Some members of the FKBP family also contain other functional domains or motifs. FKBPs have been reported to play roles in diverse processes such as protein folding, cellular signaling, and transcription, and have been implicated in several diseases (1-3).
    FKBP10, also known as FKBP65 (65 kDa FK506-binding protein), has four tandem PPIase domains and is an endoplasmic reticulum (ER) resident protein, where it modulates the folding and trafficking of secretory proteins. FKBP10 plays an important role in collagen folding and secretion and its mutation is associated with osteogenesis imperfecta (4-6), and it is considered as a therapeutic target for idiopathic pulmonary fibrosis (IPF) (7,8). Recent reports suggest that FKBP10 may be a biomarker or therapeutic targets for several different cancers (9-11).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.